Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung

Robert T. Eagan, Robert E. Lee, Stephen Frytak, Thomas R. Fleming, Edward T. Cregan, James N. Ingle, Larry K. Kvols

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Sixty-eight evaluable patients with unresectable adenocarcinoma and large cell carcinoma of the lung were treated on a prospective randomized trial comparing thoracic radiation therapy (TRT) plus combination chemotherapy with either cyclophosphamide, Adriamycin and cis-platinum (CAP) or cyclophosphamide, Adriamycin (same dosages) and DTIC (CAD), 34 on each arm. Patients treated with TRT plus CAP had a better overall regression rate (59% vs 47%) and a statistically significant superiority in time to disease progression (147 days vs 303 days) and survival (217 days vs 504 days).

Original languageEnglish (US)
Pages (from-to)1401-1405
Number of pages5
JournalInternational journal of radiation oncology, biology, physics
Volume5
Issue number8
DOIs
StatePublished - Aug 1979

Keywords

  • Chemotherapy
  • Combined modality therapy
  • Lung cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this